Abingworth raises $582 million for fund supporting late-stage research
Life sciences investment group Abingworth has announced the final closing of its new Clinical Co-Development Fund at $582 million.
The Abingworth Clinical Co-Development Fund 2 (ACCD 2) was significantly oversubscribed, exceeding its target of $350 million, and closed at its hard cap.
"This new CCDF that, combined with our $465 million ABV 8 fund, brings new funds closed by Abingworth in 2021 to over $1 billion"Alongside the recent $465 million Abingworth Bioventures 8 (ABV 8) fund, Abingworth has raised more than $1 billion in new funds to invest in life science companies in the USA, UK and continental Europe developing innovative therapeutics with potential to significantly improve human health.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze